AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

about

AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma.Male germ cells support long-term propagation of Zika virus.Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells

P2860

Q50053695-7727B957-D11C-4D3D-95C0-4832B15BA1F6 Q55084434-AF9531E1-328B-499E-916E-93FDF75DB26A Q58549853-A2A38394-A356-42B9-B0F1-18424D55DADB

P2860

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

Item

http://www.wikidata.org/entity/Q39139917

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@en

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@nl

type

Item

label

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@en

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@nl

prefLabel

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@en

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@nl

P1476

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

@en

P2093

Ross A Okimoto

http://www.w3.org/2001/XMLSchema#string

Trever G Bivona

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for Gas6-Axl signalling.

Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site

axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase

Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Epithelial-mesenchymal transitions in development and disease

P304

27-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/LCTT.S60438

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28210148

http://www.w3.org/2001/XMLSchema#string

P932

5217513

http://www.w3.org/2001/XMLSchema#string

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

about

P2860

P2860

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932